Castle Hook Partners LP Acquires New Position in IQVIA Holdings Inc. (NYSE:IQV)

Castle Hook Partners LP bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 165,646 shares of the medical research company’s stock, valued at approximately $39,253,000. IQVIA makes up about 0.7% of Castle Hook Partners LP’s portfolio, making the stock its 26th largest holding. Castle Hook Partners LP owned 0.09% of IQVIA as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP bought a new stake in IQVIA in the third quarter worth approximately $27,000. Park Place Capital Corp bought a new stake in IQVIA in the third quarter worth approximately $28,000. Versant Capital Management Inc grew its position in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in IQVIA in the second quarter worth approximately $27,000. Finally, Itau Unibanco Holding S.A. bought a new stake in IQVIA in the second quarter worth approximately $29,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on IQV. Redburn Atlantic began coverage on shares of IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. The Goldman Sachs Group reduced their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. TD Cowen reduced their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Barclays reduced their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Finally, Evercore ISI reduced their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Trading Up 0.1 %

Shares of IQV stock opened at $201.44 on Thursday. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The stock has a market cap of $36.56 billion, a price-to-earnings ratio of 26.44, a P/E/G ratio of 2.10 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The firm has a fifty day moving average of $220.36 and a 200-day moving average of $226.57.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.